Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Disc Medicine, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WATERTOWN, MASS., MAY 11, 2026 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, ANNOUNCED TODAY THAT COMPANY MANAGEMENT WILL PARTICIPATE IN FIRESIDE CHATS AT TWO UPCOMING INVESTOR CONFERENCES:

DISC MEDICINE TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

NEW YORK, MAY 10, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

IRON INVESTOR NEWS: IF YOU HAVE SUFFERED LOSSES IN DISC MEDICINE, INC. (NASDAQ: IRON), YOU ARE ENCOURAGED TO CONTACT THE ROSEN LAW FIRM ABOUT YOUR RIGHTS

NEW YORK, MAY 07, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, MAY 7, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDISC MEDICINE, INC. ("DISC" OR THE "COMPANY")(NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLEPEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. - IRON

COMPLETED ENROLLMENT OF THE PHASE 3 APOLLO STUDY OF BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA (EPP); TOPLINE DATA EXPECTED IN Q4 2026 UPDATED DATA FROM PHASE 2 STUDY OF DISC-0974 IN PATIENTS WITH ANEMIA OF MYELOFIBROSIS (MF) TO BE SHARED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING AS AN ORAL PRESENTATION PROGRESSING ONGOING PHASE 2 STUDY OF DISC-3405 IN POLYCYTHEMIA VERA (PV) AND PHASE 1B STUDY OF DISC-3405 IN SICKLE CELL DISEASE (SCD), WITH DATA FROM BOTH STUDIES EXPECTED IN Q4 2026 STRONG FINANCIAL POSITION ENDING Q1 WITH APPROXIMATELY $730 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES, PROVIDING RUNWAY INTO 2029 WATERTOWN, MASS., MAY 05, 2026 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A REVIEW OF RECENT PROGRAM AND CORPORATE DEVELOPMENTS.

DISC MEDICINE REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

NEW YORK, MAY 04, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, APRIL 30, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. ("DISC" OR THE "COMPANY") (NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, APRIL 28, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. (DISC OR THE COMPANY) (NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT. 7980.

NEW YORK, APRIL 28, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, APRIL 25, 2026 (GLOBE NEWSWIRE) -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, APRIL 22, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, APRIL 21, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. (DISC OR THE COMPANY) (NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMSON BEHALF OF INVESTORS OF DISC MEDICINE, INC. - IRON

WATERTOWN, MASS., APRIL 21, 2026 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCED THAT IT WILL PRESENT DATA FROM THE RALLY-MF PHASE 2 TRIAL OF DISC-0974 IN ANEMIA OF MYELOFIBROSIS (MF) IN AN ORAL ABSTRACT SESSION AT THE UPCOMING AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, WHICH WILL BE HELD IN CHICAGO, IL ON MAY 29-JUNE 2, 2026.

DISC MEDICINE ANNOUNCES ORAL PRESENTATION OF DATA FROM RALLY-MF PHASE 2 TRIAL OF DISC-0974 IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

NEW YORK, APRIL 18, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, APRIL 16, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. ("DISC" OR THE "COMPANY") (NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLEPEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, APRIL 14, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. (DISC OR THE COMPANY) (NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK, APRIL 9, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDISC MEDICINE, INC. ("DISC" OR THE "COMPANY")(NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, APRIL 07, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. (DISC OR THE COMPANY) (NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK, APRIL 07, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, NEW YORK--(NEWSFILE CORP. - APRIL 6, 2026) - LEVI & KORSINSKY NOTIFIES INVESTORS THAT IT HAS COMMENCED AN INVESTIGATION INTO DISC MEDICINE, INC.(NASDAQ: IRON)("DISC MEDICINE, INC.") CONCERNING POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. ON FEBRUARY 13, 2026, DISC DISCLOSED THAT THE FDA HAD ISSUED A COMPLETE RESPONSE LETTER (CRL) FOR BITOPERTIN, THE COMPANY'S LEAD THERAPEUTIC CANDIDATE TARGETING EPP, A RARE GENETIC DISORDER CHARACTERIZED BY EXTREME PHOTOSENSITIVITY.

INVESTORS IN DISC MEDICINE, INC. (IRON) WARNED OF POTENTIAL SECURITIES FRAUD - CONTACT LEVI & KORSINSKY TODAY

NEW YORK, APRIL 2, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFDISC MEDICINE, INC. ("DISC" OR THE "COMPANY")(NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTIGATION EXAMINES GAP BETWEEN REPORTED FIGURES AND GAAP RESULTS AT DISC MEDICINE AHEAD OF ITS 21.9% STOCK COLLAPSE NEW YORK, APRIL 1, 2026 /PRNEWSWIRE/ --LEVI &KORSINSKY, LLP IS INVESTIGATING WHETHER DISC MEDICINE, INC. (NASDAQ: IRON) AND CERTAIN OF ITS OFFICERS FULFILLED THEIR DISCLOSURE OBLIGATIONS TO INVESTORS IN THE PERIOD LEADING UP TO THE COMPANY'S ANNOUNCEMENT OF A COMPLETE RESPONSE LETTER FROM THE FDA. SHAREHOLDERS WHO PURCHASED IRON SHARES AND INCURRED LOSSES MAY OBTAIN FURTHER INFORMATION BY CONTACTING LEVI & KORSINSKY.

IRON INVESTORS LOSE UP TO $22/SHARE -- LEVI & KORSINSKY, LLP INVESTIGATES DISC MEDICINE

NEW YORK, MARCH 31, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. (DISC OR THE COMPANY) (NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK, MARCH 31, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

LOS ANGELES, MARCH 27, 2026 (GLOBE NEWSWIRE) -- THE PORTNOY LAW FIRM ADVISES DISC MEDICINE, INC. (DISC MEDICINE" OR THE "COMPANY") (NASDAQ: IRON) INVESTORS THAT THE FIRM HAS INITIATED AN INVESTIGATION INTO POSSIBLE SECURITIES FRAUD, AND MAY FILE A CLASS ACTION ON BEHALF OF INVESTORS.

DISC MEDICINE, INC. INVESTIGATED BY THE PORTNOY LAW FIRM

WATERTOWN, MASS., MARCH 26, 2026 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCED THAT THE LAST PARTICIPANT HAS BEEN RANDOMIZED AND DOSED IN THE PIVOTAL PHASE 3 APOLLO TRIAL OF BITOPERTIN IN EPP. ORIGINALLY PLANNED AS AN N=150 STUDY, THE STUDY WAS EXPANDED TO 183 PARTICIPANTS DUE TO PATIENT AND PHYSICIAN DEMAND.

DISC MEDICINE ANNOUNCES COMPLETION OF ENROLLMENT OF PHASE 3 APOLLO TRIAL OF BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA

NEW YORK, MARCH 26, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. ("DISC" OR THE "COMPANY") (NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLEPEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTIGATION EXAMINES GAP BETWEEN REPORTED FIGURES AND GAAP RESULTS AT DISC MEDICINE AHEAD OF ITS 21.9% STOCK COLLAPSE NEW YORK, MARCH 25, 2026 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP IS INVESTIGATING WHETHER DISC MEDICINE, INC. (NASDAQ: IRON) AND CERTAIN OF ITS OFFICERS FULFILLED THEIR DISCLOSURE OBLIGATIONS TO INVESTORS IN THE PERIOD LEADING UP TO THE COMPANY'S ANNOUNCEMENT OF A COMPLETE RESPONSE LETTER FROM THE FDA. SHAREHOLDERS WHO PURCHASED IRON SHARES AND INCURRED LOSSES MAY OBTAIN FURTHER INFORMATION BY CONTACTING LEVI & KORSINSKY.

NEW YORK, MARCH 24, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. (DISC OR THE COMPANY) (NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COM OR 646-581-9980, EXT. 7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. IRON

NEW YORK, MARCH 24, 2026 (GLOBE NEWSWIRE) -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES AN INVESTIGATION OF POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, MARCH 21, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES THAT IT IS INVESTIGATING POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

DISC MEDICINE INVESTORS WHO LOST MONEY AFTER THE FDA ISSUED A COMPLETE RESPONSE LETTER FOR BITOPERTIN ARE ENCOURAGED TO CONTACT LEVI & KORSINSKY NEW YORK, MARCH 18, 2026 /PRNEWSWIRE/ -- LEVI &KORSINSKY, LLP IS INVESTIGATING DISC MEDICINE, INC. (NASDAQ: IRON) REGARDING WHETHER THE COMPANY ADEQUATELY COMMUNICATED RISKS REGARDING ITS BITOPERTIN PROGRAM BEFORE THE FDA'S ISSUANCE OF A COMPLETE RESPONSE LETTER ON FEBRUARY 13, 2026, WHICH CAUSED A 21.9% DECLINE IN SHARE PRICE. INVESTORS WHO SUFFERED LOSSES ON IRON STOCK MAY CLICK HERE FOR ADDITIONAL INFORMATION ABOUT THIS INVESTIGATION.

IRON DROPS UP TO 39% AFTER FDA CRL FOR BITOPERTIN -- LEVI & KORSINSKY, LLP INVESTIGATES

INVESTIGATION EXAMINES GAP BETWEEN REPORTED FIGURES AND GAAP RESULTS AT DISC MEDICINE AHEAD OF ITS 21.9% STOCK COLLAPSE NEW YORK, MARCH 11, 2026 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP IS INVESTIGATING WHETHER DISC MEDICINE, INC. (NASDAQ: IRON) AND CERTAIN OF ITS OFFICERS FULFILLED THEIR DISCLOSURE OBLIGATIONS TO INVESTORS IN THE PERIOD LEADING UP TO THE COMPANY'S ANNOUNCEMENT OF A COMPLETE RESPONSE LETTER FROM THE FDA. SHAREHOLDERS WHO PURCHASED IRON SHARES AND INCURRED LOSSES MAY OBTAIN FURTHER INFORMATION BY CONTACTING LEVI & KORSINSKY.

Disc Medicine, Inc.

IRON

Price

Financial Reports

No items found.

Press Releases

Disc Medicine, Inc.

IRON.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IRON